
Topic
Formulary Strategy
Tiering, exclusions, preferred products, step therapy, and how access teams prepare the evidence packet.

Pricing & Access· May 29, 2026 · 10 min read
By Ran Chen#HIV#Infectious Disease#Prior Authorization

Pipeline· May 27, 2026 · 7 min read
Antibody-drug conjugate access landscape: ADC coverage and pipeline watch
By Ran Chen#ADC#HER2#Prior Authorization

Pipeline· May 27, 2026 · 7 min read
ASCO 2026 pipeline evidence preview for formulary and access teams

Pipeline· May 26, 2026 · 8 min read
CagriSema pre-approval evidence review for obesity access teams
By Ran Chen#GLP-1#Amylin Analog#Obesity

Approvals· May 26, 2026 · 8 min read
Novel FDA drug approvals Q1-Q2 2026: the fifteen drugs and their formulary implications
By Ran Chen#FDA Approval#Novel Drug Approvals#GLP-1

Pricing & Access· May 26, 2026 · 7 min read
Veppanu coverage guide for ER+/HER2- breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic

Pricing & Access· May 25, 2026 · 9 min read
CGRP inhibitor access landscape: eight drugs, coverage, and payer criteria in 2026
By Ran Chen#CGRP#CNS and Migraine#Coverage Access

Pricing & Access· May 25, 2026 · 9 min read
PCSK9 inhibitor access landscape: Repatha, Praluent, Leqvio, and Lerochol in 2026
By Ran Chen#PCSK9#Cardiovascular#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026
By Ran Chen#JAK Inhibitor#Immunology#Coverage Access